ImmuneOncia Therapeutics, Inc. (KOSDAQ:424870)
South Korea flag South Korea · Delayed Price · Currency is KRW
2,890.00
+85.00 (3.03%)
At close: Sep 4, 2026

ImmuneOncia Therapeutics Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-29,306-27,363-5,6878,864-3,492-60,490
Depreciation & Amortization
845.07890.411,0511,0311,0811,026
Loss (Gain) From Sale of Assets
---0.771.383.18
Stock-Based Compensation
151.48409.46981.91,3113,9911,948
Other Operating Activities
116.33-269.92-5,982-19,648-10,76748,945
Change in Accounts Receivable
65.39421.83-410.83622.65-710.85-
Change in Unearned Revenue
-----4,9526,884
Change in Other Net Operating Assets
1,8273,136-4,623-518.09-452.73-292.68
Operating Cash Flow
-26,301-22,775-14,670-8,337-15,301-1,976
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-375.15-329.97-86.87-428.43-36.21-101.34
Sale (Purchase) of Intangibles
-156.05-137.74-52.09--52.4-4.85
Investment in Securities
--12,1001,900-5,0006,0002,708
Other Investing Activities
-423.98-545.95-32.696.71-8.47-840
Investing Cash Flow
-955.18-13,1141,728-5,3325,9031,762

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Repaid
--51.87-48.87-103.65-232.1-210.93
Net Debt Issued (Repaid)
-54.16-51.87-48.87-103.65-232.1-210.93
Issuance of Common Stock
82,77636,0212598,000-6,000
Other Financing Activities
-891.2-69.1-3.18-0--
Financing Cash Flow
81,83135,900206.967,896-232.124,289

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
0-4.09-40.44218.5
Miscellaneous Cash Flow Adjustments
-0-0--0--
Net Cash Flow
54,57511.34-12,731-5,773-9,59024,293

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-26,676-23,105-14,757-8,766-15,337-2,078
Free Cash Flow Growth
------
Free Cash Flow Margin
--20776.54%-2254.59%-7968.93%-198.32%-5779.96%
Free Cash Flow Per Share
-350.96-329.02-262.08-167.13-294.29-44.72
Levered Free Cash Flow
-16,799-13,443-10,722-4,331-11,1882,384
Unlevered Free Cash Flow
-16,797-13,440-10,718-4,329-11,1882,384

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
4.275.126.93---
Cash Income Tax Paid
58.21355.61-11.0450.1815.815.98
Change in Working Capital
1,8923,558-5,034104.56-6,1166,591